{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:10:04Z","timestamp":1792692604764,"version":"4.5.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Several chimeric antigen receptor T cells (CAR T) targeting CD19 have induced profound and prolonged remission for refractory\/relapsed (R\/R) B-cell lymphoma. The risk of secondary malignancies, especially myeloid neoplasms, is of particular concern in the CAR T community, which still remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Four patients with R\/R B-cell lymphoma after CD19 CAR T therapy diagnosed with secondary myeloid neoplasms (SMN) from 2 hospitals in eastern China were presented, including 3 with myelodysplastic syndrome (MDS) and 1 with acute myeloid leukemia (AML). Using single-cell RNA sequencing (scRNA-seq), we compared the cellular components of bone marrow (BM) samples obtained from one of these MDS patients and a health donor. We also provided a review of recently published literature concerning SMN risk of CAR T therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Relevant demographic, clinical, laboratory, therapeutic and outcome data were collected and presented by chart review. In our case series, the male-female ratio was 3.0 and the median age at MDS onset was 61.25 years old (range, 50-78). Median number of previous systemic therapies was 4.5 (range, 4-5), including autologous hematopoietic stem cell transplantation (auto-HSCT) in one patient. BM assessments prior to CAR T therapy confirmed normal hematopoiesis without myeloid neoplasms. Moreover, for 3 patients with SMN in our series, cytogenetic analysis predicted a relatively adverse outcome. In our experience and in the literature, treatment choices for the patients with SMN included allogeneic hematopoietic stem cell transplantation (allo-HSCT), hypomethylating agent (HMA), period filgrastim, transfusions and other supportive care. Finally, treatment responses of lymphoma, together with SMN, directly correlated with the overall survival of this community. Of note, it appeared that pathogenesis of MDS wasn\u2019t associated with the CAR T toxicities, since all 4 patients experienced a pretty mild CRS of grade 1-2. Additionally, scRNA-seq analysis described the transcriptional alteration of CD34+ cells, identified 13 T\/NK clusters, and also indicated increased cytotoxic T cells in MDS BM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study illustrated the onset and progression of SMN after CD19 CAR T therapy in patients with R\/R B-cell lymphoma, which provides useful information of this uncommon later event.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2022.1063986","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:57:30Z","timestamp":1673571450000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":37,"title":["Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory\/relapsed B-cell lymphoma: Case series and review of literature"],"prefix":"10.3389","volume":"13","author":[{"given":"Aiqi","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhe","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aibin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015789","article-title":"CAR T cells as a second-line therapy for large b-cell lymphoma: a paradigm shift","volume":"139","author":"Westin","year":"2022","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European society for blood and marrow transplantation (EBMT) and the joint accreditation committee of ISCT and EBMT (JACIE) and the European haematology association (EHA)","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-00456-y","article-title":"Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells","volume":"18","author":"Shalabi","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19008","article-title":"Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions","volume":"8","author":"Valent","year":"2017","journal-title":"Oncotarget"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: Myeloid and Histiocytic\/Dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/s41556-018-0165-5","article-title":"Publisher correction: Tracing the temporal-spatial transcriptome landscapes of the human fetal digestive tract using single-cell RNA-sequencing","volume":"20","author":"Gao","year":"2018","journal-title":"Nat Cell Biol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"14049","DOI":"10.1038\/ncomms14049","article-title":"Massively parallel digital transcriptional profiling of single cells","volume":"8","author":"Zheng","year":"2017","journal-title":"Nat Commun"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","article-title":"Comprehensive integration of single-cell data","volume":"177","author":"Stuart","year":"2019","journal-title":"Cell"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.02.021","article-title":"A distinct expression of various gene subsets in CD34+cells from patients with early and advanced myelodysplastic syndrome","volume":"34","author":"Vasikova","year":"2010","journal-title":"Leukemia Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the international working group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e106788","DOI":"10.1371\/journal.pone.0106788","article-title":"Gene expression profiling identifies IRF4-associated molecular signatures in hematological malignancies","volume":"9","author":"Wang","year":"2014","journal-title":"PloS One"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1159\/000479837","article-title":"High expression of AHSP, EPB42, GYPC and HEMGN predicts favorable prognosis in FLT3-ITD-Negative acute myeloid leukemia","volume":"42","author":"Zhu","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31825fa501","article-title":"Alpha-hemoglobin-stabilizing protein is a sensitive and specific marker of erythroid precursors","volume":"36","author":"Raess","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000139","article-title":"Alpha-hemoglobin-stabilizing protein: An effective marker for erythroid precursors in bone marrow biopsy specimens","volume":"24","author":"Yu","year":"2016","journal-title":"Appl Immunohisto M M"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12954","article-title":"Peroxiredoxin 2 expression is increased in neutrophils of patients with refractory cytopenia with multilineage dysplasia","volume":"166","author":"Kazama","year":"2014","journal-title":"Brit J Haematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiolchem.2017.01.002","article-title":"Bipartite network analysis reveals metabolic gene expression profiles that are highly associated with the clinical outcomes of acute myeloid leukemia","volume":"67","author":"Xie","year":"2017","journal-title":"Comput Biol Chem"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1452210","article-title":"Distinct transcriptomic and exomic abnormalities within myelodysplastic syndrome marrow cells","volume":"59","author":"Im","year":"2018","journal-title":"Leukemia Lymphoma"},{"key":"B19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large b-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1697814","article-title":"Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)","volume":"61","author":"Nahas","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e002287","DOI":"10.1136\/jitc-2020-002287","article-title":"Pooled safety analysis of tisagenlecleucel in children and young adults with b cell acute lymphoblastic leukemia","volume":"9","author":"Levine","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.254045","article-title":"Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large b-cell lymphoma","volume":"106","author":"Strati","year":"2021","journal-title":"Haematologica"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of Large b cell lymphoma in the united states","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2020.10.002","article-title":"Late effects after chimeric antigen receptor T cell therapy for lymphoid malignancies","volume":"27","author":"Chakraborty","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.11.3273","article-title":"Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation","volume":"95","author":"Pedersen-Bjergaard","year":"2000","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2022.030","article-title":"De novo and therapy-related myelodysplastic syndromes: Analogies and differences","volume":"14","author":"Leone","year":"2022","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.33","article-title":"Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS clinical research consortium","volume":"31","author":"Zeidan","year":"2017","journal-title":"Leukemia"},{"key":"B29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.leukres.2017.01.024","article-title":"Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic disease","volume":"55","author":"Annereau","year":"2017","journal-title":"Leuk Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"106196","DOI":"10.1016\/j.leukres.2019.106196","article-title":"The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies","volume":"84","author":"Otoukesh","year":"2019","journal-title":"Leuk Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.04.025","article-title":"Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes","volume":"36","author":"Klimek","year":"2012","journal-title":"Leukemia Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12313","article-title":"Epi-immunotherapy for cancers: rationales of epi-drugs in combination with immunotherapy and advances in clinical trials","volume":"42","author":"Xu","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01787","article-title":"Decitabine-mediated epigenetic reprograming enhances anti-leukemia efficacy of CD123-targeted chimeric antigen receptor T-cells","volume":"11","author":"You","year":"2020","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41467-020-20696-x","article-title":"Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming","volume":"12","author":"Wang","year":"2021","journal-title":"Nat Commun"},{"key":"B35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.beha.2019.02.008","article-title":"Therapy-related myeloid neoplasms in lymphoma survivors: Reducing risks","volume":"32","author":"Al-Juhaishi","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.2.565","article-title":"Leukemia following low-dose total body irradiation and chemotherapy for non-hodgkin's lymphoma","volume":"14","author":"Travis","year":"1996","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01627.x","article-title":"Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT lymphoma and late effects working parties. European group for blood and marrow transplantation","volume":"106","author":"Milligan","year":"1999","journal-title":"Br J Haematol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0987-6","article-title":"Second cancer incidence in CLL patients receiving BTK inhibitors","volume":"34","author":"Bond","year":"2020","journal-title":"Leukemia"},{"key":"B40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cam4.799","article-title":"Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed\/refractory multiple myeloma patients","volume":"6","author":"Kotchetkov","year":"2017","journal-title":"Cancer Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1200\/JCO.2003.07.113","article-title":"Treatment-related myelodysplasia and acute leukemia in non-hodgkin's lymphoma patients","volume":"21","author":"Armitage","year":"2003","journal-title":"J Clin Oncol"},{"key":"B42","article-title":"Incidence and characterization of secondary myelodysplastic syndromes following autologous transplantation","volume":"85","author":"Del Canizo","year":"2000","journal-title":"Haematologica"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.5.947","article-title":"Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies","volume":"18","author":"Micallef","year":"2000","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic b cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrc.2016.112","article-title":"The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia","volume":"17","author":"Sperling","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/cells11030580","article-title":"Immune dysfunction, cytokine disruption, and stromal changes in myelodysplastic syndrome: A review","volume":"11","author":"Lynch","year":"2022","journal-title":"Cells"},{"key":"B47","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.exphem.2022.04.002","article-title":"Recurrent transcriptional responses in AML and MDS patients treated with decitabine","volume":"111","author":"Upadhyay","year":"2022","journal-title":"Exp Hematology"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(01)00736-6","article-title":"Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia","volume":"29","author":"Kook","year":"2001","journal-title":"Exp Hematol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1063986\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:57:33Z","timestamp":1673571453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1063986\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2022.1063986"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1063986","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,13]]},"article-number":"1063986"}}